Amicus Therapeutics, Inc. (FOLD): Small-Cap Biotech with Large Hedge Fund Ownership

Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s lead drug candidate is migalastat, which targets Fabry disease. An estimated 1 in 40,000 to 60,000 males...

Keep Reading →